Inducing synthetic lethality using PARP inhibitors

Current Clinical Pharmacology

Volumn 5, Issue 3, 2010, Pages 192-195

  Boss, David S ^a   Beijnen, Jos H ^a,b,c   Schellens, Jan H M ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

BRCA deficient; Olaparib; PARP; Repair mechanism; Synthetic lethality

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AG 14361; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CARBOPLATIN; GEMCITABINE; INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CHEMOSENSITIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA METHYLATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HUMAN; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE STRANDED DNA BREAK; SOMNOLENCE; THROMBOCYTOPENIA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 78649273622     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791498798     Document Type: Review

References (20)

1. Jemal A, Siegel R, Ward E. et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
3. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
4. Plummer R, Jones C, Middleton M. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 7917-23.
5. Plummer R, Lorigan P, Evans J, et al First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM), J Clin Oncol 2006; 24: Abstract 8013.
6. Bedikian AY, Papadopoulos NE, Kim KB, et al. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 2009; 27: 756-63.
7. Horton TM, Jenkins G, Pati D, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009; 8: 2232-42.
8. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
9. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
10. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-98.
11. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
12. Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer, J Clin Oncol 2009; 27: Abstr.CRA501.
13. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009; 27: Abstr. 5500.
14. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009; 9 (Suppl 2): S73-S81.
15. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009; 27: Abstract 3.
16. Tong WM, Yang YG, Cao WH, et al. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 2007; 26: 3857-67.
17. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079-84.
18. Edwards SL, Brough R, Lord CJ, et al Resistance to therapy caused by intragenic deletion in BRCA2, Nature 2008;451:1111-15.
19. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-20.
20. Iglehart JD, Silver DP. Synthetic lethality a new direction in cancer-drug development. N Engl J Med 2009; 361: 189-91.